Related Experiment Video
Updated: Jul 31, 2026
09:35
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
Published on: February 2, 2018
Gene therapy for inherited hyperbilirubinemias
N Roy-Chowdhury1, A Kadakol, B S Sappal
1Department of Medicine, Marion Bessin Liver Research Center, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10467, USA.
Summary
Gene therapy offers a promising alternative to liver transplantation for Crigler-Najjar syndrome type 1 (CN-1). Research in Gunn rats shows effective correction of bilirubin metabolism disorders, paving the way for clinical application.
Area of Science:
- Biochemistry
- Genetics
- Hepatology
Background:
- Crigler-Najjar syndrome type 1 (CN-1) is a severe inherited disorder of bilirubin metabolism.
- Current treatment is limited to orthotopic liver transplantation.
- The Gunn rat serves as a valuable animal model for CN-1 research.
Purpose of the Study:
- To evaluate the efficacy of cell and gene therapies for CN-1.
- To explore novel therapeutic strategies beyond liver transplantation.
- To assess the potential for partial correction of UGT1A1 activity.
Main Methods:
- Ex vivo gene therapy using genetically modified hepatocytes.
- In vivo gene transfer via adenovirus and SV40-based vectors.
- In vivo site-directed mutagenesis for genetic correction.
Main Results:
- Significant success achieved with both ex vivo and in vivo gene therapy approaches.
- Modest but significant correction of the genetic defect observed with site-directed mutagenesis.
- Validation of effective gene therapy methods in the Gunn rat model.
Conclusions:
- Gene therapy has been successfully validated in Gunn rats for CN-1.
- Cell and gene therapies show potential as future treatments for CN-1.
- Despite challenges, clinical application of gene therapy for CN-1 is anticipated.
More Related Videos
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:31Translation
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:25Jaundice
Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...